About 90% of those with familial hypercholesterolemia have not been diagnosed or treated for it, leaving them more vulnerable for COVID-19 infection and its complications.
The approval was based on data from the phase 3 ODYSSEY HoFH trial, which evaluated Praluent in 69 adults with HoFH who were on other LDL-C-lowering therapies.
A team of researchers investigated the longitudinal association between high HDL-C levels, HDL-C variability, and the risk of developing Parkinson disease.
Patients with stable chest pain had four distinct patterns of metabolic phenotypes which had unique coronary artery disease trajectories and major adverse cardiovascular event risk profiles.
What do the new guidelines and recommendations advise regarding patient selection and the most appropriate clinical use of CAC scoring for ASCVD risk assessment?
Autopsy studies have shown that aortic and coronary artery atherosclerotic lesions are present in toddlers and progresses into adulthood. This study explores the development of coronary atherosclerosis due to non–HDL-C over three stages of life.
